ImmunoGen’s IMGN632 Receives the US FDA’s Breakthrough Therapy Designation for Relapsed or Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm

 ImmunoGen’s IMGN632 Receives the US FDA’s Breakthrough Therapy Designation for Relapsed or Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm

ImmunoGen to Sell Residual Royalty Rights for Kadcyla (ado-trastuzumab emtansine) to OMERS

Shots:

  • The US FDA has granted BTD for IMGN632 to treat relapsed or refractory BPDCN
  • The BTD was based on findings from the BPDCN cohort of the first-in-human study of IMGN632, for which initial data were presented in ASH 2019. Updated data from the IMGN632 monothx. BPDCN dose expansion cohort will be presented at ASH in Dec’2021
  • MGN632 is a CD123-targeting ADC and is currently evaluated in multiple cohorts, including monothx. for patients with BPDCN and MRD+ AML following frontline induction therapy and in combinations with Vidaza (azacitidine) and Venclexta (venetoclax) for patients with relapsed/refractory AML

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: PRNewswire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post